DALLAS, June 22, 2022 /PRNewswire/ — Susan G. Komen for Healing®the world’s leading organization for the fight against breast cancer, awards $21.7 million to fund 48 new research projects at 26 distinguished academic medical institutions across the United States that focus on improving patient outcomes – especially for people with the most aggressive breast cancers or who have experienced a recurrence or metastases. With this investment, Komen now supports over 152 active research projects representing over $115 million in financing.
Susan G. Komen awards $21.7 million to fund 48 new research projects focused on improving patient outcomes
“The investment we are announcing today in a broad portfolio of cutting-edge research will help advance breast cancer care and improve outcomes for all people diagnosed with breast cancer, including underserved populations. served and those with few treatment options,” said Intelligent Victoria Wolodzkoplease from Assignment at Susan G. Komen. “With this investment, we are supporting some of the best breast cancer researchers who share our mission and bring hope to everyone affected by breast cancer as we move closer to curing breast cancers. “
of total $21.7 million rewarded today:
- 79% support research focused on the most aggressive breast cancers, metastases and recurrences;
- 33% support clinical trials;
- 20% support research focused on eliminating disparities in breast cancer;
“We still have a lot to learn about aggressive breast cancers and breast cancers that recur and metastasize. This critical research investment from Susan G. Komen will help us unravel the biology of breast cancers to better understand how to prevent breast cancer recurrence and metastasis, and develop more treatment options, including new treatments for people with metastatic breast cancer,” said Jennifer PietenpolPh.D., Susan G. Komen Chief Scientific Advisor.
Pietenpol is also the Benjamin F. Byrd, Jr. Professor of Oncology, Scientific and Strategic Director, and Executive Vice President for Research at Vanderbilt University Medical Center.
Komen Research Grants are awarded to the following researchers at 26 preeminent U.S. institutions:
Julie Palmer, Sc.D., MPH, Boston University
Jennifer LigibelMD, FASCO, Dana-Farber Cancer Institute
Nancy LinMD, Dana-Farber Cancer Institute
Kornelia PolyakMD, Ph.D., Dana-Farber Cancer Institute
Sara TolaneyMD, MPH, Dana-Farber Cancer Institute
Nikhil WagleMD, Dana-Farber Cancer Institute
Sunil BadveMD, FRCPath, Emory University School of Medicine
Maria SosaPh.D., Icahn School of Medicine at Mount Sinai
Tarah Ballingerdoctor, Indiana University
Pedram RazaviMD, Ph.D., Memorial Sloan Kettering Cancer Center
Jorge Reis FilhoMD, PhD, FRCPath, Memorial Sloan Kettering Cancer Center
Sohrab ShahPh.D., Memorial Sloan Kettering Cancer Center
Lisa CoussensPh.D., Oregon Health and Science University
Yibin Kangdoctorate, princeton university
Hai WangPhD, Roswell Park Cancer Institute
Christine CurtisPhD, MS, Stanford University Medicine School
Melinda Tellidoctor, Stanford University Medicine School
Allison KurianMD, M.Sc., Stanford University Medicine School
Haruka ItakuraMD, Ph.D., Stanford University Medicine School
Daniel HollernPh.D., Salk Institute for Biological Studies
Reshma JagsiMD, D.Phil., University of Michigan
Melissa Troesterdoctorate, University of North Carolina at Chapel Hill
Angela DeMicheleMD, MSCE, University of Pennsylvania
Adrian Leedoctorate, University of Pittsburgh
Steffi Oesterreichdoctorate, University of Pittsburgh
Alana Welmdoctorate, University of Utah Huntsman Cancer Institute
Amelie RamirezDr. PH, MPH, UT Health San Antonio
Mariana Chávez MacGregorMD, MSc, FASCO, UT MD Anderson Cancer Center
Sharon GiordanoMD, MPH, FASCO, UT MD Anderson Cancer Center
Srinivas MalladiPhD, UT Southwestern Medical Center
Tuya Paldoctor, Vanderbilt University Medical Center
Ben Ho ParkMD, Ph.D., Vanderbilt University Medical Center
Jennifer Pietenpoldoctorate, Vanderbilt University Medical Center
Sonya ReidMD, Ph.D., Vanderbilt University Medical Center
Cynthia MaMD, Ph.D., University of Washington
Rulla Tamini, Sc.D., Weil Cornell College of Cornell University
Mariya Rozenblitdoctor, Yale University
Lajos PusztaiMD, D.Phil., Yale University
Komen has invested over $1 billion in breast cancer research in the 40 years since its founding, more than any other nonprofit, and second only to the US government.
About Susan G. Komen®
Susan G. Komen® is the world’s leading non-profit breast cancer organization, working to save lives and eradicate breast cancer forever. Komen has an unparalleled, comprehensive 360-degree approach to fighting this disease on all fronts and supporting millions of people in the United States and countries around the world. We advocate for patients, drive breakthroughs in research, improve access to high-quality care, provide direct patient support, and empower people with trusted information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly researching the remedies of tomorrow. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social media at www.komen.org/contact-us/follow-us/.
CONTACT: Amanda DeBard
Susan G. Komen
(972) 701-2131
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/susan-g-komen-invests-21-7-million-in-research-focused-on-improving-outcomes-for -breast-cancer-patients-301572742.html
SOURCE Susan G. Komen for Healing